Dr. Daniel Koller is a Head BB Biotech at Bellevue Asset Management AG and a Head-Investment Management at BB Biotech AG. He joined Bellevue Asset Management in 2004 and since 2010 he heads the management of BB Biotech AG. He was previously employed as Head-Compliance by Oz Holding AG, Private Equity Investor by Equity4life AG, an Equity Analyst by UBS Warburg, Inc., Auditor by Ernst & Young AG, and a Member-Management Board by Patrimonium Swiss Real Estate Fund. Dr. Koller holds a Master's degree in Biochemistry from the Swiss Federal Institute of Technology (ETH) Zurich and a Ph.D. in Biotechnology from the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd. Zurich.